SALT LAKE CITY - Scientists report a significant step toward combatting two degenerative brain diseases that chip away at an individual's ability to move, and think. A targeted therapy developed by ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The trial will evaluate VO659, an antisense ...
A team led by Specially Appointed Associate Professor Tomohiko Ishihara and Professor Osamu Onodera at Niigata University, along with Professor Yoshitaka Nagai at Kindai University, conducted a ...
The FDA has granted orphan drug designation to Cure Rare Disease’s CRD-002, an antisense oligonucleotide therapeutic for the treatment of spinocerebellar ataxia (SCA), including spinocerebellar ataxia ...
Worldwide, only a handful of patients are known to suffer from episodic ataxia type 6, a neurological disease that causes transient loss of muscle control. The cause lies in a mutation that changes a ...
The Department of Neurology at Niigata University and the National Center of Neurology and Psychiatry (NCNP) have identified pathogenic thresholds for the CAG repeat units (RU) of the CACNA1A gene ...
Bill Nye The Science Guy Lends His Unique Voice to Raise Awareness of Rare Neurodegenerative Disease
MINNEAPOLIS--(BUSINESS WIRE)--Bill Nye, who has helped make science a part of pop culture for a generation of adults and children, is now using his acclaimed platform to educate people about Ataxia, a ...
Friedreich’s ataxia is a chronic, progressive neurological condition that leads to impaired muscle coordination. This can affect balance and mobility as well as speech and heart health. Friedreich’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results